🔓 Free Teaser Reference Card Cardiology / Anticoagulation
How the 2026 ACC/AHA guideline changes lipid clinic workflows with absolute LDL-C targets, non-sequential nonstatin selection, and universal Lp(a) testing.
🔓 Free Teaser Reference Card Geriatrics
Evidence-based frameworks for pharmacist-led deprescribing of PPIs, benzodiazepines, opioids, anticholinergics, and antihyperglycemics.
🔓 Free Teaser Reference Card Infectious Disease / Antimicrobials
Evidence-based guidance on antibiotic duration and beta-lactam infusion optimization for practicing pharmacists.
🔓 Free Teaser Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Finerenone emerges as the safer choice for CKD patients.
🔓 Free Teaser Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Tenecteplase speeds up stroke thrombolysis compared to alteplase.
🔓 Free Teaser Guideline Rheumatology / Immunology Confirmatory Grade: Moderate
New EULAR guidelines redefine RA management with DMARDs.
🔓 Free Teaser Guideline Dyslipidemia Practice-changing Grade: Moderate
The 2026 ACC/AHA/Multisociety guideline introduces lower treatment goals, formal risk equations, and mandates Lp(a) assessment for dyslipidemia pharmacists.
🔓 Free Teaser Guideline Diabetes Practice-changing Grade: Moderate
Introduces expanded diabetes screening and diagnostic recommendations across diverse populations for pharmacy practice.
🔓 Free Teaser Guideline Hypertension Practice-changing Grade: Moderate
The 2025 AHA/ACC Guideline introduces PREVENT-based CVD risk, new secondary hypertension triggers, and major changes in initial drug therapy for pharmacists managing hypertension.
🔓 Free Teaser Analysis Critical Care / ICU
The A2B trial evaluates sedation strategies on extubation timing in critical care.
🔓 Free Teaser Guideline Immunization Practice-changing Grade: Moderate
The 2025 ACIP adult schedule features universal and risk-based expansions for pneumococcal, RSV, and polio vaccines, plus product, schedule, and note updates directly relevant to pharmacists.
🔓 Free Teaser Analysis Cardiology / Anticoagulation Confirmatory Grade: Moderate
The largest, most rigorous trial of in-hospital sodium-glucose cotransporter-2 inhibitor initiation was formally neutral, but pooled trial data continue to support early inpatient start for hospitalized heart failure patients.
🔓 Free Teaser Guideline AFib/Antithrombotics Practice-changing Grade: Moderate
Major changes in stroke risk assessment, anticoagulant preferences, and DOAC over warfarin guidance will alter daily pharmacist management of AFib patients.
🔓 Free Teaser Guideline Beers Criteria Practice-changing Grade: Moderate
The 2023 AGS Beers Criteria update introduces significant modifications and new recommendations impacting antihyperglycemics, anticoagulants, anticholinergics, and select drug–disease interactions for older adults.
🔓 Free Teaser Guideline COPD Practice-changing Grade: Moderate
The GOLD 2026 update brings significant changes impacting risk stratification, exacerbation management, biologics, and vaccination in COPD care.